Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

EST Cathie Wood’s ARK Investment bought 178.1K shares of Crispr Therapeutics (CRSP) today Published first on TheFly – the ...

We expect CRISPR Therapeutics CRSP to surpass expectations when it reports third-quarter 2024 results. In the last reported ...

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has been given an average recommendation of “Hold” by the nineteen brokerages that are covering the company, Marketbeat Ratings reports. Two ...

The US FDA has cleared an investigational new drug (IND) application for HG202, by HuidaGene Therapeutics. This drug is the ...

Biotechs like CRISPR Therapeutics (NASDAQ: CRSP) can be tricky to invest in, as it isn't always obvious whether management's ...

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, ...

Leavell Investment Management Inc. decreased its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 54.9% in the 3rd quarter, according to the company in its most recent ...

Ph.D., Chief Executive Officer and Chairman of CRISPR Therapeutics. "In addition to the continued momentum of CASGEVY's ...

A patient with sickle cell disease died while participating in a clinical trial of a CRISPR-based treatment from Beam Therapeutics, threatening to overshadow early signals of effective gene editing.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...